分子腫瘍診断市場- 世界の産業規模、シェア、動向、競合、機会、予測、製品タイプ別、技術別、用途別、がんタイプ別、エンドユーザー別、地域別、競争市場別、2020-2030年

分子腫瘍診断の世界市場規模は2024年に35億4,000万米ドル、2030年には78億4,000万米ドルに達すると予測され、予測期間中のCAGRは14.17%で成長します。

慢性疾患、特にがんの罹患率の上昇により市場は急拡大しており、これが高度な診断ソリューションの需要を促進しています。分子腫瘍診断は、分子レベルでがんを検出するために使用される専門的な検査を指し、病気の存在を知らせる遺伝物質、タンパク質、バイオマーカーを特定します。このアプローチは、早期発見、標的治療、患者の転帰の改善をサポートします。認知度の向上、次世代シークエンシング（NGS）などの技術の進歩、個別化医療への投資の拡大などが市場成長に寄与しています。さらに、厳しい規制の枠組みや精密腫瘍学への世界のシフトが、分子診断プラットフォームの技術革新を促しています。世界中のヘルスケアシステムが早期発見と効率的な疾患管理を重視していることから、分子腫瘍診断市場は先進国および新興国市場全体で持続的な拡大が見込まれています。

市場促進要因

世界のがん罹患率の上昇と早期発見への需要の高まり

主な市場課題

高コストと高度診断技術へのアクセス制限

主要市場動向

分子診断における人工知能と機械学習の統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の分子腫瘍診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（機器、キットおよびアッセイ、ソフトウェア）
  • 技術別（蛍光in-situハイブリダイゼーション（FISH）、次世代シークエンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、免疫組織化学（IHC）、フローサイトメトリー、その他の技術）
  • 用途別（調査、臨床）
  • がんの種類別{固形腫瘍（乳がん、卵巣がん、前立腺がん、肺がん、大腸がん、その他の固形腫瘍）、血液がん（リンパ腫、白血病、多発性骨髄腫、その他の血液悪性腫瘍）}
  • エンドユーザー別（病院、診断センター、リファレンスラボ、製薬会社、バイオテクノロジー企業、学術調査機関）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024）
• 市場マップ
  • 製品タイプ別
  • 技術別
  • 用途別
  • がんの種類別
  • エンドユーザー別
  • 地域別

第6章 北米の分子腫瘍診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の分子腫瘍診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の分子腫瘍診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア

第9章 南米の分子腫瘍診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの分子腫瘍診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威/サービス

第14章 世界の分子腫瘍診断市場：SWOT分析

第15章 競合情勢

• Sysmex Corporation
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• HTG Molecular Diagnostics, Inc.
• Danaher Corporation
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bayer AG

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global Molecular Oncology Diagnostics Market was valued at USD 3.54 billion in 2024 and is projected to reach USD 7.84 billion by 2030, growing at a CAGR of 14.17% during the forecast period. The market is expanding rapidly due to the rising incidence of chronic diseases, particularly cancer, which is driving the demand for advanced diagnostic solutions. Molecular oncology diagnostics refer to specialized tests used to detect cancer at the molecular level, identifying genetic materials, proteins, and biomarkers that signal the presence of disease. This approach supports early detection, targeted therapy, and improved patient outcomes. Increased awareness, advances in technology such as next-generation sequencing (NGS), and growing investments in personalized medicine are all contributing to market growth. In addition, stringent regulatory frameworks and a global shift toward precision oncology are encouraging innovation in molecular diagnostic platforms. As healthcare systems worldwide emphasize early detection and efficient disease management, the molecular oncology diagnostics market is poised for sustained expansion across developed and emerging regions.

Key Market Drivers

Increasing Global Cancer Incidence and Demand for Early Detection

The rising global prevalence of cancer is a major factor propelling growth in the molecular oncology diagnostics market. According to the World Health Organization (WHO), nearly 10 million people died from cancer in 2020, with the incidence rate expected to rise by 47% by 2040, reaching over 28 million new cases annually. This alarming increase has led to a heightened focus on early detection and precision diagnostics to improve treatment outcomes and reduce healthcare burdens. Molecular diagnostics offer a pathway for identifying cancer-related mutations, chromosomal changes, and gene expression profiles even before clinical symptoms appear. Technologies like PCR, NGS, and microarrays are pivotal in enabling personalized treatment strategies and enhancing prognosis accuracy. Governments and research bodies are investing heavily in cancer diagnostics infrastructure; for example, the U.S. National Cancer Institute allocated over $7 billion in 2023 for cancer research, with a strong emphasis on molecular diagnostic tools. These developments underscore the growing importance of molecular oncology diagnostics in combating the global cancer burden.

Key Market Challenges

High Cost and Limited Accessibility of Advanced Diagnostic Technologies

Despite technological progress, the high cost of molecular oncology diagnostics remains a critical barrier to widespread adoption. Advanced testing methods like next-generation sequencing and multiplex PCR panels require expensive reagents, equipment, and skilled professionals, making them inaccessible in many low- and middle-income countries. A single NGS test can cost between $1,000 and $5,000, limiting affordability for patients and straining underfunded healthcare systems. Furthermore, insufficient diagnostic infrastructure, particularly in rural areas, exacerbates disparities in healthcare access. Challenges include a lack of molecular pathology labs, inadequate cold chain systems, and a shortage of trained personnel. Even in developed nations, inconsistent reimbursement policies hinder the adoption of newer molecular tests. According to the World Bank, healthcare expenditure in low-income nations averages about 5% of GDP, compared to more than 10% in high-income countries. This disparity underscores the urgent need for policy support, public-private partnerships, and cost-reduction strategies to bridge the accessibility gap in molecular diagnostics.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning in Molecular Diagnostics

A transformative trend in the molecular oncology diagnostics market is the integration of artificial intelligence (AI) and machine learning (ML) technologies to streamline and enhance genomic data analysis. As diagnostic platforms generate increasingly complex datasets, AI and ML provide tools to analyze patterns, classify cancer subtypes, and predict patient responses more accurately and rapidly than manual methods. These technologies can process thousands of variants simultaneously, identifying clinically relevant mutations and helping in treatment selection. Deep learning models are also being used to enhance the accuracy of image-based diagnostics and to interpret multi-omics data in real-time. Governments are supporting AI development through major funding initiatives, such as the NIH's Bridge2AI program in the U.S. and the UK's Industrial Strategy Challenge Fund. These efforts are catalyzing the adoption of AI-driven diagnostics, making molecular oncology testing more efficient, scalable, and accessible across the globe.

Key Market Players

• Sysmex Corporation
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics, Inc.
• HTG Molecular Diagnostics, Inc.
• Danaher Corporation
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bayer AG

Report Scope:

In this report, the Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type:

• Instruments
• Kits and Assays
• Software

Molecular Oncology Diagnostics Market, By Technology:

• Fluorescence In-Situ Hybridization (FISH)
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Flow Cytometry
• Other Technologies

Molecular Oncology Diagnostics Market, By Application:

• Research
• Clinical

Molecular Oncology Diagnostics Market, By Cancer Type:

• Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors)
• Blood Cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)

Molecular Oncology Diagnostics Market, By End User:

• Hospitals and Diagnostic Centers
• Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Molecular Oncology Diagnostics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molecular Oncology Diagnostics Market.

Available Customizations:

Global Molecular Oncology Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
  • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
  • 5.2.3. By Application (Research, Clinical)
  • 5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
  • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
  • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
  • 5.2.7. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Product Type
  • 5.3.2. By Technology
  • 5.3.3. By Application
  • 5.3.4. By Cancer Type
  • 5.3.5. By End User
  • 5.3.6. By Region

6. North America Molecular Oncology Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Cancer Type
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Cancer Type
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Cancer Type
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Cancer Type
      • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Cancer Type
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Cancer Type
      • 7.3.1.2.5. By End User
  • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Cancer Type
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Cancer Type
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Cancer Type
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Cancer Type
      • 7.3.5.2.5. By End User

8. Asia-Pacific Molecular Oncology Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Cancer Type
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Cancer Type
      • 8.3.1.2.5. By End User
  • 8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Cancer Type
      • 8.3.2.2.5. By End User
  • 8.3.3. India Molecular Oncology Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Cancer Type
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Cancer Type
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Cancer Type
      • 8.3.5.2.5. By End User

9. South America Molecular Oncology Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Cancer Type
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Cancer Type
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Cancer Type
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Cancer Type
      • 9.3.3.2.5. By End User

10. Middle East and Africa Molecular Oncology Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Cancer Type
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Cancer Type
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Cancer Type
      • 10.3.2.2.5. By End User
  • 10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Cancer Type
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products/Services

14. Global Molecular Oncology Diagnostics Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Sysmex Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Myriad Genetics, Inc.
• 15.4. HTG Molecular Diagnostics, Inc.
• 15.5. Danaher Corporation
• 15.6. QIAGEN N.V.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. Agilent Technologies, Inc.
• 15.9. Illumina, Inc.
• 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer